Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AMAG Pharmaceuticals Inc Reaffirms FY 2013 Revenue Guidance


Tuesday, 23 Apr 2013 04:05pm EDT 

AMAG Pharmaceuticals Inc reiterated guidance for fiscal 2013 and expects total revenues of between $73 million and $77 million, including Feraheme U.S. net product sales of between $63 million and $67 million; revenue from royalties, ex-U.S. product sales and milestones of approximately $10 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $76 million for fiscal 2013.